Transplantation of microencapsulated umbilical-cord-blood-derived hepatic-like cells for treatment of hepatic failure

Abstract

Transplantation of microencapsulated hepatic-like cells derived from umbilical cord blood cells could preliminarily alleviate the symptoms of AHF rats.

Hepatocyte-Like Cells Derived from Human Amniotic Epithelial Cells Can Be Encapsulated Without Loss of Viability or Function In Vitro

“…This would allow the delivery of large numbers of HLC, which may be able to provide immediate support to liver function. Indeed, a recent study showed that encapsulated HLC generated from umbilical cord blood cells and grafted into the peritoneal cavity was able to rescue rats with acute hepatic failure [53]. HLC derived from hAEC secrete some of the immunomodulatory factors produced by the parental cells, but soluble HLA-G was significantly lower [22].…”

Recent Advances in Derivation of Functional Hepatocytes from Placental Stem Cells

“…Moreover, hematologic parameters such as ALT, AST and total bilirubin were significantly different between encapsulated and non-encapsulated cells. In addition, after 1-2 weeks post-transplantation, the authors observed the presence of fibrous tissue surrounding microcapsules in the greater omentum [124].…”

“…Undifferentiated hAECs were transplanted in SCID/beige mice. Albumin, AFP, BSEP, CYPs and over 30 markers were analyzed by real time PCR [124] Human Amniotic epithelial cells [135] Abbreviations: FBS, fetal bovine serum; IGF-I,insulin growth factor-I; OSM, oncostatin M; AFP, α-fetoprotein; FGF, fibroblast growth factor; ITS, insulin-transferrin-sodium selenite; CK-18, cytokeratin-18; HepPar-1, hepatocyte-paraffin-1; CK-19, cytokeratin-19; AAT, α-1-antitrypsin; TAT, tyrosine aminotransferase; HNF-3β, hepatic nuclear factor-3 β; LDLR, receptor low density lipoprotein; G6P, glucose-6 phosphatase, EGF, endothelial growth factor, bFGF, basic fibroblast growth factor; CYP3A4, cytochrome P450 3A4 subunit; HNF-4α, hepatic nuclear factor-4α; G6PD, glucose-6-phosphate dehydrogenase; ; CYP1A1, cytochrome P450 1A1 subunit; CYP2B6, cytochrome P450 2B6, CYP1A2, cytochrome P450 1A2 subunit; CYP2C8, cytochrome P450 2C8; subunit; CYP2D6, cytochrome P450 2D6 subunit; CYP2C9, cytochrome P450 2C9; subunit CYP2C19, cytochrome P450 2C19 subunit; CYP2E1 cytochrome P450 2E1 subunit; AHR, Aromatic hydrocarbon receptor, PXR, pregnane × receptor; CAR, constitutive aldosterone receptor; MMP2, metalloproteineasi-2; MMP9, metalloproteineasi-9;TIMP-1,tissue inhibitor metalloproteinases-1; PDGF, platelet-derived growth factor; Il1 β, interleukin-1; Il-2, interleukine-2; IL-6, interleukin-6; Il-10,interleukine-10;Il-13, interleukine-13; INFγ ,interferone-γ ; TNFα, tumor necrosis factor-α; TGFβ1, transforming growth factor β1;ALT, alanine aminotransferase; TBIl, total bilirubin levels in serum; TO, tryptophan 2,3 dioxygenase; TPO, thrombopoietin; SCF, stem cell factor; Flt Zheng and co-workers [134] showed that AFSCs expressing IL-1Ra (interleukin-1 receptor antagonist) may improve fulminant hepatic failure (FHF) in an in vivo model. The authors showed that administration of cells prevented liver failure and increased animals survival.…”

Translational Regenerative Medicine—Hepatic Systems

“…Liver matrix bolstered the phenotype of hepatoblasts when used as a substrate in vitro compared to collagen I alone. Liver proteins including growth factors, adhesion molecules, and matrix collagens have been included in the encapsulation process to maintain the function of different liver cell types in vivo [137,138]. Further assays are required to distinguish which components of the liver matrix are the greatest contributors to cell viability and phenotype.…”